OHR Pharmaceutical, Inc., a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine in combination with Lucentis injections, which completed Phase II clinical trials for the treatment of retinal diseases, including wet form of age-related macular degeneration, retinal vein occlusion, and diabetic retinopathy. It is also developing a sustained release ocular drug delivery platform technology. OHR Pharmaceutical, Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OHRP
Previous Symbol
CUSIPN/A
Phone212-682-8452
Debt
Debt-to-Equity RatioN/A
Current Ratio5.50
Quick Ratio5.50
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.41 per share
Price / Book0.32
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-23,810,000.00
Net MarginsN/A
Return on Equity-65.19%
Return on Assets-56.79%
Miscellaneous
Employees4
Outstanding Shares56,470,000
Market Cap$7.71 million
OptionableOptionable
OHR Pharmaceutical (NASDAQ:OHRP) Frequently Asked Questions
What is OHR Pharmaceutical's stock symbol?
OHR Pharmaceutical trades on the NASDAQ under the ticker symbol "OHRP."
How were OHR Pharmaceutical's earnings last quarter?
When is OHR Pharmaceutical's next earnings date?
What price target have analysts set for OHRP?
1 analysts have issued 12 month target prices for OHR Pharmaceutical's shares. Their forecasts range from $7.00 to $7.00. On average, they expect OHR Pharmaceutical's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 5,183.0% from the stock's current price. View Analyst Price Targets for OHR Pharmaceutical.
What is the consensus analysts' recommendation for OHR Pharmaceutical?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OHR Pharmaceutical in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for OHR Pharmaceutical.
Has OHR Pharmaceutical been receiving favorable news coverage?
News stories about OHRP stock have been trending somewhat positive on Saturday, according to InfoTrie. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OHR Pharmaceutical earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days.
Who are some of OHR Pharmaceutical's key competitors?
Some companies that are related to OHR Pharmaceutical include Oncomed Pharmaceuticals (OMED), Heat Biologics (HTBX), Lipocine (LPCN), VIVUS (VVUS), AzurRx BioPharma (AZRX), GTX (GTXI), Agile Therapeutics (AGRX), Sernova (SEOVF), Adial Pharmaceuticals (ADIL), Novus Therapeutics (NVUS), DiaMedica Therapeutics (DMAC), IMMURON LTD/S (IMRN), Trillium Therapeutics (TRIL), Akari Therapeutics (AKTX) and SCYNEXIS (SCYX).
Who are OHR Pharmaceutical's key executives?
OHR Pharmaceutical's management team includes the folowing people:
- Dr. Jason Scott Slakter, CEO, Pres & Director (Age 60)
- Mr. Samuel Backenroth, CFO, VP of Bus. Devel. & Sec. (Age 34)
- Dr. Glenn L. Stoller M.D., Chief Scientific Officer (Age 54)
- Dr. Marlene Modi, Head of Preclinical & Regulatory Affairs
How do I buy shares of OHR Pharmaceutical?
Shares of OHRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OHR Pharmaceutical's stock price today?
One share of OHRP stock can currently be purchased for approximately $0.1325.
How big of a company is OHR Pharmaceutical?
OHR Pharmaceutical has a market capitalization of $7.71 million. OHR Pharmaceutical employs 4 workers across the globe.
What is OHR Pharmaceutical's official website?
How can I contact OHR Pharmaceutical?
OHR Pharmaceutical's mailing address is 800 THIRD AVENUE 11TH FLOOR, NEW YORK NY, 10022. The biotechnology company can be reached via phone at 212-682-8452 or via email at [email protected]
MarketBeat Community Rating for OHR Pharmaceutical (NASDAQ OHRP)
MarketBeat's community ratings are surveys of what our community members think about OHR Pharmaceutical and other stocks. Vote "Outperform" if you believe OHRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OHRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
